Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients

Completed · Not applicable

Conditions studied: Cerebrovascular Accident, Moyamoya Disease

In brief

Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya disease and stroke patients

Key facts

Study ID

NCT01419275

Run by

Stanford University

People needed

126

Starts

2009-04-01

Expected to finish

2013-11-01

Last updated by the study team

2017-08-30

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Moyamoya Patient Inclusion Criteria:
• Men and non-pregnant women, at least 21 years of age.
• Outpatients seen at the Stanford Neurosurgery and Neurology Departments.
• Ability to comply with all studies.
• Inclusion of Moyamoya patients with Sulfa allergies.
• Patients diagnosed with or suspected to have Moyamoya disease.
• Stroke Patient Inclusion Criteria:
• Men and non-pregnant women, at least 21 years of age.
• Patients admitted to the inpatient Stanford Stroke Service for stroke-like symptoms, less than 24 hours from last time seen normal.
• Ability to comply with all studies.
• Clinical Patient Acetazolamide MRI Inclusion Criteria:
• Men and non-pregnant women, at least 21 years of age.
• Patients admitted to the inpatient Stanford Stroke Service or Neurosurgical -Service for symptoms compatible with cerebrovascular disease.
• Ability to comply with all studies.
• Normal Subject Inclusion Criteria:
• Ability to comply with the MRI study.

You may not qualify if…

• Level of consciousness score of 2 or greater as defined by the NIH stroke scale.
• Symptoms likely related to psychoactive drugs or patients with symptoms related to an active inflammatory disease such as AIDS, meningitis, or cerebritis.
• Psychiatric or substance abuse disorder or dementia that interferes with evaluation or interpretation of the neurologic and mental assessment of these patients.
• Informed consent cannot be obtained either from the patient or legal representative.
• Severe coexisting or terminal systemic disease that limits life expectancy or that may interfere with the conduct of the study.
• Symptoms related to an alternative diagnosis such as seizures or migraine.
• Patients receiving any thrombolytic agent or receiving acute stroke investigational drug therapies during the 30-day study.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.